Reviva Pharmaceuticals (RVPH) Projected to Announce Quarterly Earnings on Thursday

Reviva Pharmaceuticals (NASDAQ:RVPH) is expected to be posting its Q3 2026 resultson Thursday, November 12th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.19. On average, analysts expect Reviva Pharmaceuticals to post ($2.96) EPS for the current fiscal year and ($1.26) EPS for the next fiscal year.

Reviva Pharmaceuticals Stock Down 6.5%

RVPH opened at $0.34 on Tuesday. The stock has a market cap of $4.50 million, a PE ratio of -0.19 and a beta of 0.61. The business’s fifty day simple moving average is $0.47 and its 200 day simple moving average is $1.38. Reviva Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $15.40.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system, inflammatory and cardiometabolic disorders. The company’s lead product candidate is brilaroxazine, formerly known as RP5063, a novel serotonin-dopamine activity modulator being developed for psychiatric and neurological conditions.

Brilaroxazine has been evaluated in clinical studies for schizophrenia and has also been investigated for other potential indications, including bipolar disorder, major depressive disorder, dementia-related behavioral symptoms and pulmonary arterial hypertension.